Hepatitis B/C, Cirrhosis




Feronsure (Interferon alfa – 2a, recombinant) is a sterile protein product for use by injection. Feronsure manufactured by recombinant DNA technology that (employs a genetically engineered Escherichia coli bacterium containing DNA that codes for the human protein). Interferon alfa – 2a, recombinant is a highly purified protein containing 165 amino acids, and it has an approximate molecular weight of 19,200 daltons.

Feronsure is supplied in sterile, white, lyophilized powder. The reconstituted preparation with 1 ml solvent (containing 0.9% benzyl alcohol) results in a clear, colorless solution.

Feronsure is supplied as an injectable solution in vials and prefilled syringes.  Solution for injection is sterile, clear, and colorless.





Each vial of lyophilized powder contains: Recombinant Human Interferon alfa -2a           3 MIU  and 1 vial  solvent (1 mL)


Each glass vial of 1 mL contains: Recombinant Human Interferon alfa - 2a                       3 MIU


Each prefilled syringe of  0.5 mL contains: Recombinant Human Interferon alfa -2a            3 MIU



Feronsure is indicated for the treatment of:

- Hairy cell leukaemia.

- AIDS patients with progressive, asymptomatic Kaposi's sarcoma who have a CD4 count >


- Chronic phase Philadelphia-chromosome positive chronic myelogenous leukaemia.

- Cutaneous T-cell lymphoma.

- Adult patients with histologically proven chronic hepatitis B who have markers for viral

replication,i.e., those who are positive for HBV DNA or HBeAg.

- Adult patients with histologically proven chronic hepatitis C who are positive for HCV

antibodies or HCV RNA and have elevated serum alanine aminotransferase (ALT) without liver


- The efficacy of interferon alfa-2a in the treatment of hepatitis C is enhanced when combined

with ribavirin.

- Feronsure should be given alone mainly in case of intolerance or contraindication to ribavirin.

- Follicular non-Hodgkin's lymphoma.

- Advanced renal cell carcinoma.

- Patients with AJCC stage II malignant melanoma (Breslow tumour thickness > 1.5 mm, no

lymph node involvement or cutaneous spread) who are free of disease after surgery.


Administration route: SC or IM injection.




- A history of hypersensitivity to recombinant interferon alfa-2a or to any of the excipients.

- Patients with severe pre-existing cardiac disease or with any history of cardiac illness. No direct cardiotoxic effect has been demonstrated, but it is likely that acute, self-limiting toxicities (i.e., fever, chills) frequently associated with administration of Feronsure may exacerbate pre-existing cardiac conditions.

- Severe renal, hepatic or myeloid dysfunction.

- Uncontrolled seizure disorders and/or compromised central nervous system function.

- Chronic hepatitis with advanced, decompensated hepatic disease.

- Chronic hepatitis who have been recently treated with immunosuppressive agents.




Storage: Store in the refrigerator at 2°C - 8°C. Do not freeze. Keep away from light.

The solution for injection should be inspected visually for particulates and discoloration before administration. 

Shelf Life: 24 months from manufacturing date

Reconstituted solution is stable for 30 days at temperatures of 2°C - 8°C

Packing Units:

Box of 01 vial of lyophilized powder  and  1 vial  solvent (1 mL)

Box of 01, 05 vial(s) of solution for injection (1 mL)

Box of  01, 06, 12 prefilled syringe(s) of solution for injection (0.5 mL)

Hi-Tech Park considered good...

National Assembly Vice Chairwoman Nguyen Thi Kim Ngan said in her tour to the Hi-Tech Park in Ho...

CPhI Worldwide 2013 – Frankfurt,...

Well-known as an international interactive company in the biopharmaceutical market, Nanogen Biopharmaceutical...